PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey. Show more

400 Alexander Park Drive, Princeton, NJ, 08540, United States

Biotechnology

Healthcare

Market Cap

69.86M

52 Wk Range

$0.85 - $1.88

Previous Close

$1.31

Open

$1.30

Volume

87,722

Day Range

$1.29 - $1.32

Enterprise Value

-23.39M

Cash

93.55M

Avg Qtr Burn

-19.68M

Insider Ownership

3.35%

Institutional Own.

69.52%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rezatapopt (PC14586) Details Solid tumor/s	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rezatapopt (PC14586) (p53 reactivator) +/- azacitidine Details Acute myeloid leukemia	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rezatapopt/ PC14586 (p53 reactivator) + KEYTRUDA Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.